FAM167A-AS1/LIN28B Regulates the Warburg Effect to Promote Gastric Cancer Progression by Stabilizing C-Myc Mrna

Tao Yu,Meng-yan Xie,Yuan Fang,Ting-ting Xu,Yu-tian Pan,Yong-qian Shu,Tong-peng Xu

DOI: https://doi.org/10.2139/ssrn.4121723

2022-01-01

SSRN Electronic Journal

Abstract:Background: LIN28B plays a critical role in the Warburg effect. However, the underlying mechanism remains elusive. It is recently reported that LIN28B could collaborate with IGF2BP3, which is capable of reading RNA methylation on c-MYC mRNA. Therefore, we investigate whether LIN28B employs a similar mechanism in gastric cancer to promote the Warburg effect. Besides, the association between LIN28B and c-MYC transcripts might be reinforced by specific lncRNAs.Methods: Effects of LIN28B on gastric cancer was confirmed in vitro and in vivo. On the basis of bioinformatics analysis, the association between LIN28B and c-MYC mRNA and the role of m6A were identified by RNA immunoprecipitation (RIP) and luciferase reporter assays. We further performed RIP-seq to search for long non-coding RNAs (lncRNAs) participating in LIN28B binding process. Chromatin immunoprecipitation was used to show the impact of c-MYC on transcription of LIN28B and lncRNAs.Findings: We identified that LIN28B could bind to c-MYC mRNA by recognizing m6A and maintain its stability. Correspondingly, c-MYC promoted the transcription of LIN28B. The c-MYC/LIN28B axis promoted the aerobic glycolysis in gastric cancer. We screened out an oncogenic lncRNA, FAM167A-AS1, which was combined by both LIN28B and IGF2BP3 and transcriptionally regulated by c-MYC. FAM167A-AS1 enriched in cytoplasm could help LIN28B stabilize c-MYC mRNA. FAM167A-AS1/LIN28B could activate the PI3K/AKT signaling pathway as well.Interpretation: FAM167A-AS1 might work as a scaffold to support the interaction between c-MYC mRNA and LIN28B. The c-MYC/FAM167A-AS1/LIN28B axis promoted the aerobic glycolysis and tumor progression including cell proliferation and migration. FAM167A-AS1 has the potential to become a new target for gastric cancer treatment.Funding Information: This work was supported by Jiangsu province 333 high level Talents Project (TP Xu), the Natural Science Foundation of Jiangsu Province (BK20211381 to TP Xu), the National Natural Science Foundation of China (82172889 to YQ Shu), Social development-key program-clinical frontier technology of Jiangsu Province (BE2020783 to YQ Shu).Declaration of Interests: The authors declare no potential conflicts of interest.Ethics Approval Statement: The protocol was approved by the Committee on the Ethics of Animal Experiments of the Nanjing Medical University.